Endonovo Therapeutics (ENDV) Shares Outstanding (Weighted Average) (2016 - 2023)
Endonovo Therapeutics has reported Shares Outstanding (Weighted Average) over the past 13 years, most recently at $276.4 million for Q3 2023.
- Quarterly results put Shares Outstanding (Weighted Average) at $276.4 million for Q3 2023, up 125.53% from a year ago — trailing twelve months through Sep 2023 was $276.4 million (up 125.53% YoY), and the annual figure for FY2022 was $139.2 million, up 132.64%.
- Shares Outstanding (Weighted Average) for Q3 2023 was $276.4 million at Endonovo Therapeutics, up from $263.9 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for ENDV hit a ceiling of $276.4 million in Q3 2023 and a floor of $481827.0 in Q1 2019.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $50.1 million (2021), compared with a mean of $80.2 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 99.85% in 2019 and later skyrocketed 2531.36% in 2020.
- Endonovo Therapeutics' Shares Outstanding (Weighted Average) stood at $697305.0 in 2019, then surged by 1651.87% to $12.2 million in 2020, then surged by 389.83% to $59.8 million in 2021, then soared by 132.64% to $139.2 million in 2022, then soared by 98.52% to $276.4 million in 2023.
- The last three reported values for Shares Outstanding (Weighted Average) were $276.4 million (Q3 2023), $263.9 million (Q2 2023), and $251.4 million (Q1 2023) per Business Quant data.